Member Info for tecbadger

So in my limited experience in investing i have noticed a similar trend that most rampers/derampers share.

There is no nuance, There is no critical thinking. They usually present a piece of information or an event in whichever light suits their agenda and never discuss how it could be other things. Its eiher an unconscious confirmation bias or a conscious attempt to manipulate.

For example todays director sell who really knows the reason? Could it be that theres a limited close period to record some profits for directors right now? Possible, the seller holds many more options so banking upwards of 300K now may very well be a tempting option. Could it be a lack of confidence in the companies forward looking performance? Also possible however my take is on the balance of this with all the other hints and indicators we are seeing that in general the company trajectory is positive.

I havent had the time to be exhaustative but thats how you do it. Assess both sides and come to your own conclusions.

Of course i didnt Kev but, as an investor, i also dont think panicking and flooding the board with multiple negative threads is warranted either

Proper Eeyore our kev. Only ever pops up for a good moan

Well....

This got super toxic super fast

Kev we could all sit here with whatifs all day mate.

What if Bill Gates puts a PO in for Eleventy million ABC-19s?

He would not be able to sell these shares if there were negative insider information either. Amazing how the trolls come scuttling from under the rock as soon as theres an opportunity to be negative

Yawny Yawny Dibs Snore zzzzzzzz

If I were 16 and offered 4500 quid to get a disease that's very low risk to me id snap their hand off!

What have you got against Atari?

I agree Twatcher 75M a day seems nuts unless there is outside sourcing or stockpiling ahead of a short blitz

Because on Monday 22nd a scruffy overpromoted c***womble will be blustering his mouth on TV about a path out of lockdown. Give it a few hours for him to be corrected and then we should see LFTs prime and centre stage.

Depends on the risk appetite really. Usually you will manufacture 3 batches of a product and test them for verification and validation that they meet requirement specifications as the final step in a technical transfer.

This batches could be small scale (low business risk) or large scale (high business risk) obviously if at large scale there will be plenty left after testing to sell

i prefer a basil brush "Boom boom" when i ramp myself. To each their own i suppose.

Sensitivity and specificity are essentially meaningless in that size of study. Need to see the bigger study to get a more accurate feel. To be fair I haven't seen data from a large scale mologic study yet either. All I've seen from them was 28 samples.

Nextyearrodders there could well be a strategy to start off using mologics test and then in a few months transfer to avactas test afterwards after it has been ce marked an technical transferred.

All we can do is speculate

This is great performance today. H2 2020 financials already announced so hopefully a strong push on from here with the expected newsflow.

GLR1990 i like Avacta and their pipeline. I hope they pull this test off im just wary of the outstanding work needing to be done to bring it to market. Unless theres lots going out in the background in parallel which we havent been notified of i would say they are looking at Q2

Regulator, good to see you here i just popped over for a bit of a nosy this AM. Alas i am a mere M.Sc. as i didnt feel another 3 years work for the PhD would be fruitful particularly as i was more commercially orientated than academic.

Its a very good point Bushmaster. We will likely never know why they sold. Everything is pure speculation. The next 2 weeks should provide plenty of information as the UK gov looks to lay out the roadmap out of lockdown

AVCT investors are more bullish and they have a lot of equity with Institutional Investors which helps to stabilise them. Every positive RNS for ODX that does not contain forecast numbers or actual sales has become an opportunity for traders

GLR1990 in studies with such low numbers the sensitivity and specificity are not so informative. I.e 1 failure in 28 samples affects the percentage hugely.

This is why many scientists prefer positive and negative percent agreement calculations for diagnostic performance. These tools take into account study size and the scores would be very low with 28 or 30 samples.

In short the study size used for both products is not large enough to be truly informative yet.